Bank of America’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-706,665
| Closed | -$51M | – | 6668 |
|
|
2025
Q4 | $51M | Sell |
706,665
-1,018,521
| -59% | -$65.8M | ﹤0.01% | 1549 |
|
|
2025
Q3 | $75.2M | Sell |
1,725,186
-114,129
| -6% | -$4.61M | 0.01% | 1402 |
|
|
2025
Q2 | $52.2M | Buy |
1,839,315
+264,827
| +17% | +$7.89M | ﹤0.01% | 1674 |
|
|
2025
Q1 | $46.5M | Buy |
1,574,488
+1,395,900
| +782% | +$43.5M | ﹤0.01% | 1660 |
|
|
2024
Q4 | $5.19M | Sell |
178,588
-1,164,431
| -87% | -$48.7M | ﹤0.01% | 3558 |
|
|
2024
Q3 | $61.7M | Buy |
1,343,019
+1,151,748
| +602% | +$50M | 0.01% | 1394 |
|
|
2024
Q2 | $7.81M | Buy |
191,271
+9,600
| +5% | +$275K | ﹤0.01% | 3193 |
|
|
2024
Q1 | $4.64M | Sell |
181,671
-78,937
| -30% | -$1.24M | ﹤0.01% | 3684 |
|
|
2023
Q4 | $2.36M | Sell |
260,608
-99,606
| -28% | -$666K | ﹤0.01% | 4237 |
|
|
2023
Q3 | $2.3M | Sell |
360,214
-326,311
| -48% | -$2.81M | ﹤0.01% | 4113 |
|
|
2023
Q2 | $7.61M | Buy |
686,525
+280,031
| +69% | +$3.51M | ﹤0.01% | 2984 |
|
|
2023
Q1 | $6.24M | Buy |
406,494
+162,134
| +66% | +$3.57M | ﹤0.01% | 3317 |
|
|
2022
Q4 | $5.42M | Buy |
244,360
+175,770
| +256% | +$2.62M | ﹤0.01% | 3322 |
|
|
2022
Q3 | $1.12M | Buy |
68,590
+14,090
| +26% | +$270K | ﹤0.01% | 4797 |
|
|
2022
Q2 | $792K | Buy |
54,500
+11,846
| +28% | +$176K | ﹤0.01% | 5096 |
|
|
2022
Q1 | $788K | Sell |
42,654
-46,452
| -52% | -$789K | ﹤0.01% | 5457 |
|
|
2021
Q4 | $2.12M | Buy |
89,106
+66,322
| +291% | +$1.58M | ﹤0.01% | 4493 |
|
|
2021
Q3 | $562K | Sell |
22,784
-9,080
| -28% | -$197K | ﹤0.01% | 5558 |
|
|
2021
Q2 | $788K | Buy |
31,864
+209
| +0.7% | +$4.86K | ﹤0.01% | 5092 |
|
|
2021
Q1 | $691K | Buy |
31,655
+18,051
| +133% | +$442K | ﹤0.01% | 5131 |
|
|
2020
Q4 | $347K | Buy |
+13,604
| New | +$397K | ﹤0.01% | 5250 |
|
Other funds holding RNAM
Bank of America's RNAM Position: Q1 2026 in Review
Bank of America sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 706,665 shares — an estimated $51M sold.
Bank of America first reported a position in RNAM in Q4 2020 and held it in 21 quarters. The position peaked at $75.2M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Bank of America reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Bank of America sold 706,665 Avidity Biosciences shares in Q1 2026, an estimated $51M.
- Bank of America first reported a position in Avidity Biosciences in Q4 2020 and held it in 21 quarters.
- Bank of America's Avidity Biosciences position peaked at $75.2M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.